The European Society for Medical Oncology (ESMO) shared a post on X:
“Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin – atezolizumab combination met their primary endpoints of survival.
Read the opinion by Alfredo Addeo in the ESMO Daily Reporter․“
More posts featuring ESMO Daily Reporter on OncoDaily.